And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to chaperone our shortest person for more lessons in the vintage driving machine, check in on the Pharmalot ancestors, and catch up on some reading and napping. And what about you? This is a good time to make time for someone special or plan a spring break. Or you could place bets on the likelihood that a wall gets built on a certain border. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

The day after Egalet bought Zorvolex, an anti-inflammatory pain reliever, the company boosted the price by nearly 70 percent, which represents the largest single brand price hike in over a year, Axios writes, citing 46Brooklyn, a nonprofit research firm that tracks pricing. As of Feb. 1, a 90-pill bottle now has a price tag of $650, compared with $383 a year ago, according to Elsevier’s Gold Standard Drug Database. The previous owner, Iroko Pharmaceutical, already raised the price by 9.4 percent on Jan. 9, making this the only drug to experience more than one increase this year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy